Treatment concerns for psychiatric symptoms in patients with COVID-19 with or without psychiatric disorders.
Level V
Where this comes from
- Record sourced from PubMed, PMID 32270760.
- Also identified by DOI 10.1192/bjp.2020.84 and PMC identifier 7190394.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Many psychiatric patients have been infected with COVID-19, and patients with COVID-19 may develop psychiatric symptoms after treatment with antiviral drugs. Given the tolerability and minimal P450 interactions, antidepressants (i.e., citalopram, escitalopram etc.), antipsychotics (i.e., olanzapine) and valproate can be considered to be safe in combination with antiviral drugs.
Medical subject headings
- Antiviral Agents
- Coronavirus Infections
- Drug Interactions
- Drug Therapy, Combination
- Mental Disorders
- Pandemics
- Pneumonia, Viral
- Psychotropic Drugs